Stockmaven_logo.png

 

advertise_with_us

 

Ads Disclaimer

 

Compugen, Ltd. (CGEN)
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on a decade long focus on in silico (by computer) prediction and selection of therapeutic and diagnostic product candidates utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen’s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) “discovery on demand” agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by our partner. In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA) - to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Evogene’s corporate Website at www.evogene.com.

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.


Business Law & Financial Ethics Company Histories - Suggested Reading
Top of page Stock Maven® Glossary Search Stock Maven®

 

About Opinion / Technical Analysis
Search Stocks and Shares: Enter Symbol (Lookup):
QuoteChart
Opinion Profile

 

 

Ads Disclaimer

 

 

 

© 2013 STOCK MAVEN: ALL RIGHTS RESERVED

Stock Maven is a registered trademark ®